Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Group sequential extensions of a standard bioequivalence testing procedure

A L Gould1

  • 1Merck Research Laboratories, West Point, Pennsylvania 19486, USA.

Journal of Pharmacokinetics and Biopharmaceutics
|February 1, 1995
PubMed
Summary

Group sequential bioequivalence testing offers a flexible approach to drug formulation trials. This method can reduce the number of observations needed, improving efficiency while maintaining statistical validity for bioequivalence assessment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Strain-level diversity of symbiont communities between individuals and populations of a bioluminescent fish.

The ISME journal·2023
Same author

Chromosome-Level Genome Assembly of the Bioluminescent Cardinalfish Siphamia tubifer: An Emerging Model for Symbiosis Research.

Genome biology and evolution·2022
Same author

Life history of the symbiotically luminous cardinalfish Siphamia tubifer (Perciformes: Apogonidae).

Journal of fish biology·2016
Same author

Segregation effects on the properties of (AuAg)₁₄₇.

Physical chemistry chemical physics : PCCP·2014
Same author

Symbiosis initiation in the bacterially luminous sea urchin cardinalfish Siphamia versicolor.

Journal of fish biology·2012
Same author

Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone.

Diabetes, obesity & metabolism·2009

Area of Science:

  • Pharmacokinetics and Drug Development
  • Biostatistics
  • Clinical Trial Design

Background:

  • Bioequivalence trials are crucial for comparing drug formulation bioavailability.
  • Regulatory standards require confidence intervals for formulation comparisons (e.g., 0.8-1.25).
  • Traditional fixed-sample designs are sensitive to variability and sample size estimations.

Purpose of the Study:

  • To introduce group sequential bioequivalence designs for enhanced trial efficiency.
  • To provide statistically valid methods for accommodating variability in bioequivalence studies.
  • To enable earlier decisions in bioequivalence trials compared to fixed-sample designs.

Main Methods:

  • Group sequential methods allow interim analyses and potential early stopping.

Related Experiment Videos

  • Designs accommodate potential misspecification of pharmacologic endpoint variability.
  • Statistical analyses remain consistent with fixed-sample design approaches.

    • Main Results:

    • Group sequential designs can lead to decisions with fewer observations approximately 60% of the time.
    • These designs offer comparable average costs to fixed-sample designs.
    • Slight adjustments to nominal significance levels (e.g., 93-94% confidence) are needed.

    Conclusions:

    • Group sequential bioequivalence testing provides an efficient alternative to fixed-sample designs.
    • The methods are adaptable for trials expecting equal or slightly different bioavailability.
    • These designs enhance statistical decision-making in drug development while managing costs.